NCT02946788 is a Phase 2 clinical trial of Minocycline in Acne Vulgaris, sponsored by BioPharmX, Inc..

Who is sponsoring NCT02946788?

NCT02946788 is sponsored by BioPharmX, Inc..

What drugs are being tested in NCT02946788?

Interventions in NCT02946788: Minocycline.

What condition does NCT02946788 study?

NCT02946788 studies Acne Vulgaris.

Is NCT02946788 still recruiting?

NCT02946788 is currently completed. Last updated 26 July 2022.

Are results published for NCT02946788?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-07-26 · How we verify

NCT02946788

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Completed Phase 2 Results posted Last updated 26 July 2022

What this trial tests

Phase 2 trial testing Minocycline in Acne Vulgaris in 20 participants. Completed in 1 June 2018.

Timeline

13 March 2017

Primary endpoint
1 June 2018

1 June 2018

Quick facts

Lead sponsor	BioPharmX, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	13 March 2017
Primary completion	1 June 2018
Estimated completion	1 June 2018
Sites	2 locations across United States

Drugs / interventions tested

Minocycline (MINOCYCLINE) — full drug profile →

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

BioPharmX, Inc. — full company profile →

Who can join

Adults 18 to 40, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Inflammatory Lesion Counts at Week 12 Primary · 12 weeks

difference in number of inflammatory lesions at week 12 as compared to baseline

Group	Value	95% CI
BPX-01 1%	22.3	10 – 32
BPX-01 2%	19.0	11 – 40

Adverse events — posted to ClinicalTrials.gov

Time frame: 8 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

BPX-01 1%

Serious: 0/8 (0%)

Deaths: 0/8

BPX-01 2%

Serious: 0/10 (0%)

Deaths: 0/10

Other adverse events (4 terms — click to expand)

Reaction	System	BPX-01 1%	BPX-01 2%
facial redness	Skin and subcutaneous tissue disorders	—	—
facial dryness	Skin and subcutaneous tissue disorders	—	—
bloody diarrhea	Gastrointestinal disorders	—	—
ear infection	Infections and infestations	—	—

Data from ClinicalTrials.gov NCT02946788 adverse events section.

Sponsor's own description

This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Minocycline

Trials testing the same drug.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other BioPharmX, Inc. trials

Trials by the same sponsor.

NCT03667222 — Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea · Phase 2 · unknown
NCT03050086 — Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02946788 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioPharmX, Inc.
Last refreshed: 26 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02946788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing